Legal & General Group Plc Takes Position in TG Therapeutics, Inc. $TGTX

Legal & General Group Plc acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 322,229 shares of the biopharmaceutical company’s stock, valued at approximately $17,703,000.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of TG Therapeutics during the 2nd quarter valued at $1,211,429,000. Vanguard Group Inc. boosted its holdings in shares of TG Therapeutics by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 15,841,002 shares of the biopharmaceutical company’s stock worth $472,220,000 after buying an additional 319,703 shares during the period. State Street Corp grew its stake in TG Therapeutics by 4.7% in the 4th quarter. State Street Corp now owns 8,479,999 shares of the biopharmaceutical company’s stock valued at $252,789,000 after buying an additional 379,380 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in TG Therapeutics by 35.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock valued at $61,144,000 after buying an additional 531,759 shares during the last quarter. Finally, Pictet Asset Management Holding SA raised its holdings in TG Therapeutics by 19.6% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,747,373 shares of the biopharmaceutical company’s stock worth $58,048,000 after acquiring an additional 286,325 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on TGTX shares. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday, July 29th. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. B. Riley Financial boosted their price objective on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Bank of America increased their target price on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. Finally, JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $63.00.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $53.93 on Monday. The firm has a market capitalization of $8.26 billion, a PE ratio of 19.68, a PEG ratio of 2.31 and a beta of 1.62. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. TG Therapeutics, Inc. has a 1-year low of $26.76 and a 1-year high of $59.30. The business’s 50 day moving average is $53.37 and its 200-day moving average is $41.91.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The business had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The firm’s quarterly revenue was up 70.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.17 EPS. Sell-side analysts predict that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.